NCT05023265Recruiting
Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT
Assessment of Quality of Life and Outcomes in Patients Treated With Stereotactic Body Radiotherapy (SBRT) for Inoperable Renal Cell Carcinoma (RCC): A Multicenter Phase II Study
Source: ClinicalTrials.gov · Last updated 28 Apr 2026
Brief summary (registry, in English)
This is a multicenter, single arm phase II study of stereotactic body radiation therapy (SBRT) for patients with medically inoperable primary renal cell carcinoma (RCC).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 5 Aug 2021
- Start date
- 8 Feb 2022
- Primary completion date
- 1 Oct 2026
- Lead sponsor
- Sunnybrook Health Sciences Centre
- Diseases
- Kidney cancer
- NCT number
- NCT05023265
What you commit to
- Study type: Interventional
- Planned participants: 70
- From 8 Feb 2022 to the primary completion date, 1 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous abdominal RT in vicinity of kidney preventing definitive SBRT
Other illness
- Evidence of distant metastatic disease
- History of major radiosensitivity syndrome
- Second invasive malignancy within the past 3 years (excluding non-melanomatous skin cancer)
Other
- Primary Lesion \>20cm
- Currently pregnant or lactating
Who the study is looking for
- Patients ≥18 years old
- Newly diagnosed RCC by biopsy (preferred) or radiologic evidence of growth on surveillance over two consecutive assessments (6-12 months)
- Primary lesion \>3 cm, or recurrent lesion following local ablative therapy
- Medically inoperable or patient who refuses surgery following assessment by experienced urologist, and discussed in a multidisciplinary setting
- ECOG 0-2
- Written informed consent
- Participants must be able to understand the English-language or with the aid of a translator
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sunnybrook Health Sciences Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.